Physician profile
Randolph Capri
NPI 1750340345
$4,095.23
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $117 · 2021: $462 · 2022: $1,188 · 2023: $1,061 · 2024: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $936.20 | 2021-2024 | |
| Merz North America, INC. | $572.50 | 2021-2023 | |
| Abbvie INC. | $424.23 | 2021-2024 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $392.91 | 2019-2024 | Winlevi, Odomzo, Blu-U |
| Leo Pharma INC. | $221.91 | 2020-2024 | Adbry |
| Pfizer INC. | $185.39 | 2023-2024 | |
| Allergan, INC. | $172.88 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $138.23 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $135.13 | 2019-2024 | |
| Galderma Laboratories, L.P. | $131.59 | 2019-2024 | |
| Ucb, INC. | $106.26 | 2019-2024 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $103.42 | 2023-2024 | Zoryve |
| Janssen Biotech, INC. | $83.44 | 2019-2023 | Tremfya |
| Amgen INC. | $83.27 | 2022-2024 | Otezla |
| Lilly USA, LLC | $73.38 | 2019-2023 | Taltz, Olumiant |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $52.44 | 2022-2024 | Opzelura |
| Biofrontera INC. | $47.19 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Epi Health, LLC | $30.35 | 2019-2022 | |
| Prugen, INC. Pharmaceuticals | $29.43 | 2019 | |
| Blueprint Medicines Corporation | $27.84 | 2023 | |
| Sanofi-Aventis U.S. LLC | $24.55 | 2020 | |
| Smith+Nephew, INC. | $23.31 | 2024 | Grafix Pl |
| Mission Pharmacal Company | $22.73 | 2019 | |
| Dusa Pharmaceuticals, INC. | $18.16 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $17.99 | 2023 | |
| Celgene Corporation | $14.71 | 2019 | |
| Sebela Pharmaceuticals INC. | $13.75 | 2023 | Naftin |
| Regeneron Healthcare Solutions, INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Capri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.